Press Release | December 13, 2017

Just Biotherapeutics China's Series B Financing selected as “China Top 10 Investment and Financing Events in Healthcare”

Hangzhou, China | December  13, 2017   - Just Biotherapeutics China (“Just China”), an organization dedicated to expanding global access to important protein therapeutics, has made the list of Sina Medicine’s 2017 list of “China Top 10 Investment and Financing Events in Healthcare”. In August this year, Just China secured $57M in Series B Financing from Temasek, Taikang, Lilly Asia Ventures (LAV), ARCH Venture Partners (ARCH), Hangzhou Economic & Technological Development Area (HEDA), Bank of China (BOC) and Bank of Hangzhou (BOH). Among the investors, LAV and ARCH also participated in Just China’s Series A Financing along with Merck and the Bill & Melinda Gates Foundation.

Click here to learn more

Press Release | August 10, 2017

Dr. Willard H. Dere and Dr. Steve Landau Join Just China to Help Promote Clinical Development and Products Cooperation Internationally

HangZhou, China | August 10, 2017 – Just Biotherapeutics China (“Just China”), an organization dedicated to expanding global access to important protein therapeutics, today announced the induction of Dr. Willard H. Dere and Dr. Steve Landau, who will serve as the chairman of its Scientific Advisory of Board and Chief Medical Officer, respectively.

Click here to learn more

Hangzhou, China  |  August 8, 2017

Hangzhou Just Biotherapeutics, Ltd.Secures Closing of Series B Financing

Company receives $57M to Further Advance Biologics Development and Clinical Trials

Hangzhou, China |  August 8, 2017  - Dedicated to developing global antibody and recombinant protein bio-therapeutics, Hangzhou Just Biotherapeutics, Ltd. (Just China), today announced the completion of its Series B funding round.

Click here to learn more

Press Release | May 4, 2017

Just Biotherapeutics China Reaches Collaboration with HISH of CMDA

Hangzhou, China | May 4, 2017 - Just Biotherapeutics China (“Just China”), an organization dedicated to expanding global access to important protein therapeutics, recently attended “The Assembly of Holistic Integrative Society of Hematology (“HISH”) of Chinese Medical Doctor Association (“CMDA”) held in Xi’an, Shaanxi. During which a strategic partnership was formed between the two parties in terms of hematology and clinical research. The assembly attracted hematology specialists from more than 30 large upper first-class hospitals. Among the attendees, there were Professor Chen Xiequn from Xijing Hospital affiliated to The Forth Military Medical University, Professor Ai Huisheng from Beijing 307 Hospital, and Professor Jin Jie from The First Affiliated Hospital of Medical School of Zhejiang University, etc.

Click here to learn more

Press Release | March 14, 2017

Just Biotherapeutics, Inc., Hangzhou Just Biotherapeutics, Ltd. and G-CON Manufacturing Announce Collaboration on State of the Art Bioprocess Facility in China

Collaboration furthers Just Biotherapeutics’ and Hangzhou Just Biotherapeutics’ shared mission to design and apply innovative technologies to dramatically expand global access to protein therapeutics

Hangzhou, China | March 14, 2017 – Just Biotherapeutics (Just), its affiliated company, Hangzhou Just Biotherapeutics (Just China) and G-CON Manufacturing today announced that the companies are working together on Just China’s state of the art biologics facility in the Hangzhou Economic & Technology Development Area (HEDA) in China. Currently under construction, the cGMP facility is expected to be completed and operational in early 2018.

Click here to learn more

Just News | February 17, 2017

Just Biotherapeutics China Scientific Advisory Board Consultant Dr. Arindam Bose Elected to the NAE

Seattle, WA | February 17, 2017 - Just Biotherapeutics China (“Just China”), an organization dedicated to expanding global access to important protein therapeutics, announced that Dr. Arindam Bose, member of its Scientific Advisory Board, is elected to the National Academy of Engineering (“NAE”). In total, the NAE has elected 84 new members and 22 foreign members, announced NAE President C.D. (Dan) Mote Jr. today. This brings the total U.S. membership to 2,281 and the number of foreign members to 249.

Click here to learn more

Press Release | August 5, 2016

Hangzhou Just Biotherapeutics Co., Ltd. Announces Its Establishment

Series A Funding Secured to Build World Class R&D Center and Manufacturing Plant

Hangzhou, China | August 5, 2016 - Dedicated to designing and applying leading monoclonal antibody technologies to meet global demand by significantly improving biologics quality and manufacturing process, Hangzhou Just Biotherapeutics Co., Ltd. (Just China) announced its establishment, its R&D and manufacturing facility located in Hangzhou Eastern High Technology Park under construction at the same time.

Click here to learn more

Press Release | August 3, 2016

Just Biotherapeutics, Inc. Secures $14M Series A2 Funding To Build Laboratory, Pilot Plant And GMP Capabilities

Bill & Melinda Gates Foundation, Merck, Lilly Asia Ventures, ARCH Venture Partners back company’s mission to expand access to biotherapeutics

Hangzhou, China | August 8, 2017 - Just Biotherapeutics, Inc., an organization dedicated to expanding global access to important protein therapeutics, today announced the closing of a $14M Series A2 financing round.

Click here to learn more

Media Coverage  |  September 25, 2015

Puget Sound Business Journal.

These former Amgen scientists just got $30M.

Here’s how they plan to change the world

By Annie Zak

Access to lifesaving drugs can sometimes be difficult to attain in the areas where the need for those medicines is highest. Some drugs might be too expensive for use in developing countries, and those countries don’t always have the infrastructure needed to support drug manufacturing facilities.

A young Seattle company is hoping to change that.

Click here for the rest of the story.

Media Coverage  |  September 18, 2015

Timmerman Report.

Just Snags $15M From Merck, Lilly, ARCH for Low-Cost Biotech Drugs

By Luke Timmerman

Startup biotech drugmakers usually aspire to make something innovative, and someday be rewarded with sky-high prices. Just Biotherapeutics wants to do the innovation piece, but it has different ideas about price. 

Click here to learn more

Press release  |  September 18, 2015

Just Biotherapeutics, Inc. Secures $15M Series A Funding To Advance

Development of Novel Technology Platform for Biologic Medicines

Merck, Lilly Asia Ventures, ARCH Venture Partners back company’s mission to expand access to biotherapeutics

Click here to learn more

Press release  |  September 2, 2015

LabKey Software Partners with Just Biotherapeutics, Inc.

New software product targets biotherapeutic research and development

Click here to learn more

Press release  |  August 9, 2015

Just Biotherapeutics, Inc. Receives Grant To Develop

Novel Technologies To Lower The Commercial Cost Of

Monoclonal Antibodies In Low Income Markets

Company will Receive up to $15M Over 5 Years From the Bill & Melinda Gates Foundation to Dramatically Expand World-Wide Access to Biotherapeutics

Click here to learn more